Bicara Therapeutics Inc. (NASDAQ:BCAX)
| Market Cap | 1.24B+35.5% |
| Revenue (ttm) | 0 |
| Net Income | -185.36M-80.5% |
| EPS | -3.10-64.9% |
| Shares Out | 65.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 775,255 |
| Open | 19.21 |
| Previous Close | 19.21 |
| Day's Range | 18.59 - 19.26 |
| 52-Week Range | 13.59 - 30.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 32.57(+73.24%) |
| Earnings Date | Nov 9, 2026 |
Bicara Therapeutics Inc. has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About BCAX
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BCAX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BCAX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BCAX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BCAX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BCAX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Clinical operations and development | $21.38M | 56.30% |
| Manufacturing and process development | $11.48M | 30.24% |
| Professional fees | $4.68M | 12.31% |
| Research | $436.00K | 1.15% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BCAX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BCAX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BCAX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $38.76M |
| IWMiShares Russell 2000 ETF | $22.33M |
| XBIState Street SPDR S&P Biotech ETF | $21.96M |
| VXFVanguard Extended Market ETF | $11.48M |
| IWOiShares Russell 2000 Growth ETF | $7.16M |
| IBBiShares Biotechnology ETF | $6.44M |
Estimated from each fund’s disclosed top holdings × AUM
BCAX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BCAX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score